Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand alone and integrated drug discovery solutions, covering all activities from target to clinic. The Company has established a unique position by assembling top class scientific experts and integrating state of the art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. lt br / gt lt br / gt Evotec has long term discovery alliances with partners including BoehringerIngelheim, CHDI, Genentech, Medimmune/AstraZeneca, Novartis and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and with Andromeda Teva in the field of diabetes and with Roche in the field of Alzheimer s disease. Evotec is built on integrated drug discovery know how of more than years and is a leading player in the drug discovery field. The Company s headquarters are located in Hamburg, Germany. Additional major operations are based in Abingdon, UK, G ttingen, Munich, Germany, Thane, India and San Francisco, USA. Evotec has more than employees worldwide.
Quote | Evotec Ag Ord (OTCMKTS:EVOTF)
Last: | $13.83 |
---|---|
Change Percent: | -0.72% |
Open: | $13.93 |
Close: | $13.83 |
High: | $13.93 |
Low: | $13.83 |
Volume: | 200 |
Last Trade Date Time: | 03/05/2024 03:00:00 am |
News | Evotec Ag Ord (OTCMKTS:EVOTF)
COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS ...
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024. The Company is going to hold a conference call to discuss the results as well as prov...
Message Board Posts | Evotec Ag Ord (OTCMKTS:EVOTF)
Subject | By | Source | When |
---|---|---|---|
chartguy89: EVOTF 5.98 Stock Charts $EVOTF 1 Month Chart | chartguy89 | investorshangout | 03/07/2014 8:52:52 AM |
chartguy89: EVOTF Stock Charts Last: +0.08 Wednesday, February 26, 2014 at 1:23:53 AM $EVOTF | chartguy89 | investorshangout | 02/26/2014 6:24:04 AM |
News, Short Squeeze, Breakout and More Instantly...
Evotec Ag Ord Company Name:
EVOTF Stock Symbol:
OTCMKTS Market:
COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS ...
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024. The Company is going to hold a conference call to discuss the results as well as prov...
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced the appointment of Aurélie Dalbiez as the Company's new Chief People Officer ("CPO"), effective 15 June 2024. Aurélie will be joining E...